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Transfer  of autoimmune  disease  by  implanting  specific  tissues  from  mice 
genetically predisposed  to autoimmunity into nonautoimmune histocompatible 
recipients is an exceptionally good way to define the etiopathogenesis of such 
disorders.  Although some autoimmune  manifestations have  been  observed  in 
normal mice transplanted with spleen or bone marrow (BM) 1 cells from NZB or 
NZB X  NZW  F~  (NZB  ×  W) mice, which are genetically prone  to a  systemic 
lupus erythematosus (SLE)-like disease (1-3), the results are questionable because 
the  recipients  usually  differ  from  the  donor  at  the  major  or  several  minor 
histocompatibility loci.  Resulting allogeneic reactions may then induce autoim- 
mune manifestations (4). 
The recent availability of BXSB mice, the males and females of which differ 
substantially  in  mortality  rates  and  expression  of SLE-like  syndromes  (50% 
mortality at 5-6 mo for males, and beyond 18 mo for females), and of congenic 
MRL mice (MRL/Mp lpr/lpr [iymphoproliferative syndrome], 50% mortality at 
5 mo, and MRL/Mp +/+ at 18 mo) (5, 6) provides the opportunity to perform 
well-controlled cell transfers to determine the importance of hemopoietic/lymph- 
oid cell abnormalities in this disease. Bone marrow and spleen cell transfer studies 
in male and female BXSB mice have already shown that this disease is expressed 
by their hemopoietic stem cell population, and that nonlymphoid or hormonal 
influences are  minimal (7,  8).  We now report our experience with similar cell 
transfers between the lpr/lpr and +/+ lines of the MRL strain. The unexpected 
finding was  that  although  these  lines  are  considered  congenic  (<1%  of their 
genomes differ) (5), unidirectional severe graft-vs.-host-like disease (GVHD) and 
lymphoid atrophy developed in the +/+  recipients of lpr/lpr  lymphoid cells or 
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their  precursors.  On  the  other  hand,  lpr/lpr  recipients  of  +/+  cells  showed 
delayed autoimmunity. 
Materials and  Methods 
Mice.  MRL/Mp  lpr/Ipr  and  MRL/Mp  +/+  mice  (H-2k),  originally  developed  by 
Murphy and Roths (5) were bred and maintained at the Scripps Mouse Colony. MRL/Mp 
lpr/lpr mice develop a variety of autoantibodies, and massive Thy-1 +, Lyt-1  + cell prolif- 
eration with lymph node hyperplasia and splenomegaly at 3-4 mo, and die with severe 
immune complex (IC) glomerulonephritis (GN) by 5 too. The congenic +/+ mice do not 
contain the lpr gene, are genetically >99% identical to the lpr/lpr line, develop late SLE, 
and die in the latter half of the second year of life (5, 6). Additional strains used in these 
studies included three immunologically normal strains (C57BL/6, C3H/St, BALB/c), and 
one strain (C57BL/6 Ipr/lpr) that, like the MRL lpr/lpr, expresses the lpr gene, develops 
lymphoid hyperplasia and autoantibodies, but sustains very mild GN (9-11). All mice used 
in this study were females and, unless otherwise stated, were 4 wk old at the time of cell 
transfers. 
Preparation  of Cells for Transfer.  Cell populations used for transfers were: spleen, BM, 
and  fetal  liver cells.  Spleen  and  fetal  liver cell suspensions  were  made  by passing the 
organs through a stainless steel screen in minimum essential medium (Gibco Laboratories, 
Grand Island, NY) supplemented with 0.02 M Hepes. BM ceils were obtained by flushing 
the  tibias  and  femurs  with  the  above  medium.  Erythrocytes  were  lysed  from  these 
preparations with 0.17 M NH4CI. The cells were then washed three times with medium 
and resuspended to  l0  s viable spleen cells/ml, 4 ×  107 BM cells/ml, and 1.6  x  107 fetal 
liver cells/ml. In some experiments, spleen or BM cells were treated with anti-Thy-l.2 
(New England Nuclear, Boston, MA.) with or without complement (C) to lyse or sensitize, 
respectively, mature T  cells.  Anti-Thy-l.2 plus C-treated spleen cells were unresponsive 
to concanavalin A  (Con A).  Furthermore,  in some experiments, BM cells were treated 
sequentially with soy bean agglutinin (SBA) and peanut agglutinin (PNA), as detailed by 
Reisner et al. (12), before transfer to eliminate mature and immature T  and B cells from 
the stem cell inoculum. 
Cell Transfers.  Recipients of cell transfers were given puramycin (Ralston-Purina, St. 
Louis, MO) in their drinking water for at least 48 h, and fasted for 24 h  before being 
given a  lethal  dose  (850  rad)  of irradiation  on  the  morning  of transfer.  They  were 
maintained on puramycin for 3 wk thereafter. 5 x  107 spleen cells,  2 x  107 BM cells,  or 
0.8 x  107 fetal liver cells were injected intravenously into each recipient. Some recipients 
were  injected  with  mixtures of lpr/lpr  and  +/+  spleen  or  BM  cells.  Recipients  were 
followed for evidence of clinical disease, especially enlarged lymph nodes, and sacrificed 
when moribund for complete autopsy and cellular studies. Serum samples were obtained 
at monthly intervals for serologic studies. 
In some studies, +/+ mice were thymectomized (13) at birth and lethally irradiated at 
1 mo for use as recipients of lpr/lpr  spleen or BM  cells.  Effective thymic removal was 
ascertained 2  wk before irradiation  by studying responsiveness to a  thymus-dependent 
antigen, sheep red blood cells (SRBC), manifested as serum hemagglutinating antibodies. 
Additionally,  some lpr/lpr  mice were thymectomized at birth and immediately given 
(under the skin at the back of the neck) whole thymus from  1-mo-old +/+ mice; 2 mo 
later, successfully transplanted animals, as judged by responsiveness to SRBC, were used 
as donors of spleen or BM cells.  Conversely, other +/+ mice were thymectomized and 
transplanted with lpr/lpr  thymuses; 2  mo later, these mice were lethally irradiated and 
reconstituted with BM cells from lpr/lpr mice. 
Histologic Studies.  Major organs from autopsied mice were weighed,  sectioned,  and 
stained with hematoxylin and eosin for microscopic examination. GN was quantitated on 
a  0-4 scale based on the intensity and extent of histologic involvement. A  grade  3 or 
higher was considered contributory to death. 
Serologic Studies.  Blood  urea nitrogen  (BUN) was determined  by Azostix strips,  as 
recommended  by  the  manufacturer  (Miles  Ames  Division,  Miles  Laboratories,  Inc., 
Elkhart,  IN). IgG was estimated by single radial immunodiffusion. Anti-single-stranded THEOF1LOPOULOS  ET  AL. 
DNA (ssDNA) and anti-double-stranded DNA, as well as IC, were measured as described 
(6). 
Cellular Studies.  Primary mixed lymphocyte reactions (MLR), primary and secondary 
cell-mediated lympholytic reactions (CML) were performed as detailed elsewhere (14). 
Suppression of proliferative responses of splenocytes from each MRL line to the T cell 
mitogen  Con  A,  or a  B  cell  mitogen,  lipopolysaccharide (LPS) (E.  coli 055:B5;  Difco 
Laboratories, Detroit, MI), by splenocytes of the opposite line was tested by incubating 
each cell type separately with the mitogens (baseline value), or together at complementing 
proportions to maintain a constant total cell number in culture (2 ×  l0 b cells in 0.2 ml). 
Con A was used at 4 pg/ml, and LPS at 2.5 gg/ml. After a 3-d incubation, proliferative 
responses were measured by the degree of [3H]thymidine incorporation in the washed 
pellet (15). Recipients' total spleen and lymph node cells, and their T  and B cell content 
were counted, at the time of sacrifice, as described (16). 
Splenomegaly Assay for GVHD.  With a modified Simonsen's assay (17), newborn +/+ 
mice were injected  intraperitoneally with  5  ×  10  7  splenocytes from  1-mo-old +/+  or 
lpr/lpr  mice. Controls were injected with saline.  10 d  later, litters were sacrificed, and 
spleen/body weight ratios were determined for both the inoculated recipients and control 
littermates. An index of spleen enlargement was computed by dividing the spleen/body 
weight ratios of the injected animals by that of thor uninjected littermates. 
Colony-forming Units (CFU).  To determine the efficiency in hemopoietic precursors of 
BM in the two MRL lines, we counted hemopoietic stem cells by the spleen colony assay 
of Till and McCulloch (18). Enough viable nucleated BM cells (105) to yield 8-20 colonies 
were injected intravenously into groups of 10-20 lethally irradiated recipients. 11 d later, 
the mice were killed, their spleens fixed in  Bouin's fluid, and the macroscopic surface 
colonies (CFU) counted. 
Results 
Spleen  Cell  Transfers.  Fig.  1  depicts  the  mortality  rates  after  spleen  cell 
transfers between  MRL lpr/lpr  and  MRL +/+  mice.  MRL lpr/Ipr  recipients of 
MRL  lpr/Ipr  spleen  cells  (MRL  lpr/lpr  ---> MRL  lpr/lpr)  had  short  life  spans, 
similar to their unmanipulated counterparts, whether the donors were  1 mo old 
(prediseased) or 5 mo old (diseased) (50% mortality ~5.2 mo posttransfer). MRL 
lpr/lpr  recipients  of syngeneic  splenocytes  developed  characteristic  dermatitis 
and  lymphadenopathy with enlarged submaxillary,  inguinal,  and axillary nodes 
100- 
80-  90°  /P~'RP  ~+/+  f341  (211 
70- 
60- 
:~  50- 
~  40- 
30" 
20- 
10" 
2  3  4  5  6  7  8  9  10  11  12  13  14 
Months 
FIGURE l.  Mortality rates in spleen cell transfers between MRL lpr/lpr and MRL +/+ mice. 
The percentage of dead animals in each group is tabulated and graphed on a monthly basis, 
counting from the day of transplantation. In the case of M  RL lpr/lpr --* M  RL lpr/IDr transfers, 
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FIGURE 2.  Mortality rates after BM cell transfers between MRL lpr/lpr and MRL +/+ mice, 
calculated as in Fig.  1. Numbers in parentheses indicate the size of each group. 
by the fourth month  posttransplantation,  although  this was not as apparent  as 
that  in  the  unmanipulated  MRL  lpr/lpr  controls.  In  contrast,  MRL  lpr/lpr 
recipients of the MRL +/+ splenocytes had a longer 50% mortality rate (9.7 mo 
posttransfer)  than  the unmanipulated  MRL lpr/lpr controls (5 too), and devel- 
oped minor  lymphadenopathy.  MRL +/+  ---* MRL +/+  recipients had  a  50% 
mortality  rate  10.2  mo  posttransfer,  compared  to  17  mo  for  unmanipulated 
female +/+  mice. The shorter life span of the former group was attributed  to 
some early deaths, apparently due to pulmonary infections. Unexpectedly, MRL 
+/+ recipients of MRL lpr/Ipr splenocytes developed a severe wasting syndrome, 
and died 2-4 mo posttransfer (50% mortality 2.2 mo posttransfer) without the 
typical  lymphadenopathy  of the  donor  strain.  In  a  group  of such  recipients 
followed closely, wasting was clinically apparent at ~ 1 mo posttransfer. 
BM Cell Transfers.  As Fig.  2  shows, the results of BM cell transfers  closely 
resembled those observed with spleen cell transfers.  MRL lpr/lpr recipients of 
MRL lpr/lpr BM cells derived from young (1 mo) or older (5 mo) donors had a 
50% mortality at around 5 mo posttransfer, and developed severe lymphadenop- 
athy.  Furthermore,  MRL  lpr/lpr  recipients  of  MRL  +/+  BM  cells  outlived 
control  MRL lpr/Ipr  mice  that  had  been  given  MRL lpr/lpr  transfers  (50% 
mortality  at  10.8  vs.  5  mo  posttransfer).  The  50%  mortality  for  MRL  +/+ 
recipients of MRL +/+ BM cells was around 12 mo posttransfer. As in the spleen 
cell transfers,  MRL +/+ recipients of MRL lpr/lpr BM cells developed a severe 
wasting  syndrome,  and  died  1-6  mo  posttransfer  (50%  survival  at  4.3  mo), 
without  the  clinical  manifestations  or  lymphadenopathy  of the  MRL  lpr/lpr 
donor  strain.  Even  at  15  d,  MRL  +/+  recipients  of MRL  lpr/lpr  cells  had 
developed  this  wasting  syndrome.  Runt  disease  also  developed  by  3-4  mo 
posttransfer in a group of MRL +/+ mice given a  mixture of 2 ×  10 7 -[-/'4- and 
2 ×  107 lpr/lpr BM cells. When 2 ×  107 +/+ BM cells were given together with 
varying  numbers  of lpr/Ipr  BM  cells,  as  few  as  5  X  106  Ipr/Ipr  cells  in  the 
inoculum (1:5 ratio of lpr/lpr to +/+ cells) caused the wasting syndrome in the 
+/+ recipients. Irradiating (250 rad) the lpr/Ipr cells before inoculation delayed 
the wasting syndrome until about 5 mo of age, and irradiation of these cells with 
500-1,000 rad completely eliminated it in +/+ recipients of cell mixtures. THEOFILOPOULOS ET  AL.  5 
Additional in vivo experiments showed that incremental injection of +/+ BM 
cells (2,  10, and 20 ×  106) into +/+ mice transplanted  1 mo earlier with lpr/lpr 
cells failed to rescue the recipients from the wasting syndrome.  Furthermore, 
injection of lethally irradiated  (MRL  lpr/lpr  x  MRL  +/+)F~  mice with  MRL 
lpr/lpr BM cells resulted in wasting and death by 3-5 mo posttransfer, whereas 
no wasting developed even at 5 mo in F~ mice reconstituted with MRL +/+ BM 
cells. Runt disease did afflict lethally irradiated C3H/St (H-2 k) mice transplanted 
with MRL lpr/lpr but not MRL +/+ BM cells. 
Histologic Studies.  MRL lpr recpients of +/+ lymphoid cells did not develop 
lpr-associated lymphoproliferation, although their lymphoid organs (spleen, thy- 
mus, and lymph nodes) showed varying degrees of immunoblastic changes, with 
increased  numbers of plasmacytoid cells.  Interestingly,  +/+  recipients  of lpr 
lymphoid cells not only failed to manifest lymphoproliferation, they showed signs 
of graft histoincompatibility. In the early stages (1-2 wk after engraftment), the 
+/+  recipients'  splenic white pulp contained pycnotic cells,  plasma cells,  and 
macrophages  (Fig.  3a),  followed  by  progressive  cellular  depletion,  complete 
hyalinization, and fibrosis of the splenic parenchyma by 4-5 mo (Fig. 3 b). Their 
thymus, BM, and lymph nodes underwent similar stages of cellular depletion and 
hyalinization. Other organs showing the histologic changes associated with graft 
histoincompatibility were  the  liver,  which  showed  focal  fibrinoid  necrosis  of 
hepatocytes, and portal triaditis with inflammatory destruction of bile ducts (Fig. 
3c),  and  the  gastrointestinal  tract  (Fig.  3d)  where  there  was  inflammatory 
infiltration  with destruction of the  mucosal epithelium.  Likewise, the bronchi 
and the inter- and intralobular ductal epithelium of salivary glands were infil- 
trated  by  mononuclear inflammatory cells.  At autopsy,  these affected  organs 
show fibrosis and sclerosis. 
Serologic Studies.  The serologic characteristics of all splenic cell recipients and 
their respective controls are depicted in Table I.  MRL +/+ ---, MRL +/+ and 
MRL lpr/lpr ~  MRL lpr/lpr  recipients resembled their corresponding unma- 
nipulated controls with respect to hypergammaglobulinemia, high levels of BUN, 
IC, and anti-DNA. In MRL lpr/lpr recipients of +/+ cells, these serologic values 
were reduced compared to those in unmanipulated lpr/lpr mice or to lpr/lpr 
lpr/lpr.  However,  +/+  recipients of lpr/lpr  cells failed  to show any  serologic 
characteristics of the donor strain; comparatively, their levels of IgG, anti-DNA, 
and IC were low. 
Cellular  Studies.  The  enlarged  lymph  nodes  (median  weight  460  mg)  of 
lpr/lpr ~  lpr/lpr mice had >94%  Thy-1 +, Lyt-1 + cells, whereas +/+ --~ lpr/lpr 
chimeras  (median  weight  130  mg)  contained  73%  Thy-1 +,  Lyt-1 +,  and  22% 
surface Ig-positive cells. Spleens of +/+  mice given lpr/lpr  splenocytes, which 
produced wasting and lymphoid atrophy, were also killed and examined for T 
and B cell composition at  15, 30, or 60 d  posttransfer (Table II). At 30 d these 
mice had ~33% as many, and at 60 d  ~0.3%  as many splenocytes as at day  15 
posttransfer,  with  a  marked  decline  in  Thy-1 + cells.  In  contrast,  the  splenic 
cellularity and frequency of T  and B cells remained unaltered in +/+ recipients 
of +/+ cells. 
Histocompatibility  Studies.  Because of the consistent development of GVHD 
in  +/+  recipients  of lpr/lpr  BM  or  spleen  cells,  possible  histocompatibility 6  lpr  GENE  IN  TRANSPLANTATION 
FIGURE 3.  Histologic findings in MRL +/+ recipients of MRL lpr/lpr  lymphoid cells. (a) 
+/+  spleens 2  wk after lymphoid cell transfer. Arrow indicates splenic arteriole, which  is 
surrounded by scattered pycnotic lymphocytes. In the surrounding white pulp, the fibrous 
stroma contains plasma cells and macrophages. (b) +/+ spleens 4.5 mo after lymphoid cell 
transfer. Arrow marks splenic arteriole in upper right, which is surrounded by fibrous, largely 
acellular stroma remaining after depletion of most of the splenic cells. (c) Hepatic portal triad 
of +/+ recipients 2 mo after cell transfer. Stars indicate the bile ducts, which are surrounded 
by inflammatory lymphoid infiltrates. (d)  Small bowel of +/+  recipients 2  mo  after cell 
transfer. Arrows of upper part of photo mark the partially denuded mucosal surface. The 
entire submucosa is infiltrated by chronic inflammatory cells. The largely uninvolved muscu- 
larus and peritoneal surface are seen at the lower portion of the photo. 
differences between  these  congenic  lines were  sought.  As shown  in  Table  III, 
lpr/lpr  and  +/+  cells  exhibited  normal  MLR  against  H-2-incompatible  cells 
(BALB/c,  H-2d), and  no reactivity against themselves or H-2-compatible alloge- 
neic cells (C3H/St,  H-2k).  Similarly (Table  IV),  the  primary  CML  against  H-2- THEOFILOPOULOS  ET  AL. 
TABLE  I 
Serologic Characteristics of Spleen Chimeras 
Anti-ssDNA 
Mice  IgG  binding  BUN  IC 
mg/ml  %  mg/ml  tag/ml 
+/+  13.4 4-  1.0  35.1  4- 6.6  15.1  ----- 9.6  67.2 4- 32.0 
lpr  31.0 4- 5.0  78.3 4- 6.4  >60.0  2,934.5  4- 793.5 
+/+---* +/+  11.2+  1.4  33.9+  13.3  16.1  4-  10.1  19.94-31.0 
lpr*--*lpr  21.24-8.0  72.0---35.7  57.34-12.7  2,569.14-11,191.7 
lpr*---~lpr  35.5 --- 7.8  76.8 --- 14.3  >60.0  ND  ~ 
+/+--~lpr  21.0---1.9  43.34-20.9  35.04-10.3  636.04-153.8 
lpr----~+/+  7.94-  1.2  25.74-20.0  11.0---9.6  21.2---24.9 
* MRL lpr/lpr donors 1 mo old. 
$ MRL lpr/lpr donors 5  mo old. 
! ND, not determined. 
TABLE  II 
Lymphoid Cell Numbers and Surface Characteristics in Spleen Cell Transfers 
Time 
Type of transfer  posttrans-  Total spleen cells 
fer  (x  10 -6)  Thy'I+  slg+ 
d  %  % 
lpr/lpr---~ +/+  15  48.7 -  6.7  25.4 4- 3.2  46.9 -  6.9 
30  16.0 4- 2.3  9.7 4-  1.8  35.8 4- 5.8 
60  0.15 4- 0.04  ND*  ND 
+/+ ---* +/+  30  63.1  +  8.8  44.3 +  4.1  42.2 4- 7.7 
60  66.5 ___ 2.4  42.3 ___ 2.4  55.8 _  3.9 
Means +  SD of five individual mice for each time point. 
* ND, not determined. 
incompatible target  cells and  secondary responses against  H-2-compatible allo- 
geneic cells were normal,  i.e.,  killing  was substantial  in  both instances.  Yet no 
primary,  and  only  weak  secondary  CML  between  the  two  MRL  lines  was 
recorded;  the  secondary  CML  was  in  no  way  comparable  to  the  secondary 
responses  seen  between  these  cells  and  C3H/St  cells,  which  differ  at  minor 
histocompatibility loci. 
Splenomegaly, tested neonatally, was unremarkable  in +/+ recipients of +/+ 
or lpr/lpr cells. The spleen/body weight ratio between uninjected and injected 
mice was 0.991:1  for +/+ cells, and 0.994:1  for lpr/lpr cells. 
Hemopoietic Precursor  Efficiency of lpr/lpr.  To  determine  whether  the  runt 
disease of +/+ recipients of lpr/lpr cells was caused by insufficient numbers of 
bemopoietic precursors in lpr/lpr BM inocula or by BM resistance phenomena 
(19), we counted CFU induced in reciprocal BM cell transfers between the two 
MRL  lines.  As  shown  in  Table  V,  lpr/lpr  BM  inocula  contained  sufficient 
numbers of pluripotent cells; somewhat more, in fact, than in -I-/+ inocula. 
Attempts  to  Overcome the  Wasting  Syndrome.  We  used  several  methods  that 
reportedly (12, 20-22) prevent GVHD caused by major or minor histocompati- 
bility differences. Treatment of the lpr/lpr BM inocula with anti-Thy-l.2 alone 
or in conjunction with C to opsonize or eliminate contaminating mature T  cells, lpr GENE  IN  TRANSPLANTATION 
TABLE III 
Mixed Lymphocyte Reaction with MRL lpr/lpr and MRL +/4- Cells 
[SH]Thymidine  Stimula- 
Responder  Stimulator  uptake*  tion index* 
cpm 
lpr/lpr  --  14,829 4- 1,778 
+/+  --  30,515 4- 1,772 
C3H/St  --  30,127 4- 3,504 
BALB/c  --  14,147 4- 3,504 
D 
lpr/lpr  lpr/lpr  16,688 4- 1,703  1.13 
+/+  34,788 4- 3,795  1.14 
C3H/St  28,111 4- 1,373  0.93 
BALB/c  119,660 4- 4,100  8.46 
lpr/lpr  +/+  22,910 4- 2,427  1.54 
+/+  36,024 ± 3,482  1.18 
C3H/St  24,908 4- 3,003  0.83 
BALB/c  118,959 4- 1,962  8.41 
lpr/lpr  BALB/c  168,458  4- 22,745  11.36 
+/+  246,506 4- 23,495  8.08 
C3H/St  231,827 -+ 11,956  7.69 
BALB/c  12,193 4- 2,110  0.86 
lpr/lpr  C3H/St  15,488 +  1,475  1.04 
+/+  34,420 + 5,204  1.13 
C3H/St  23,244 4- 3,114  0.77 
BALB/c  117,518 4- 6,462  8.31 
* Mean _+ SD of three experiments with spleen cells of l-too-old mice. 
* Stimulation indices were calculated by dividing the mean cpm in a given 
experiment by the mean cpm in the responding cells' background control 
culture. 
respectively, was unsuccessful. Similarly, treatment of lpr/lpr BM cells with PNA 
and SBA to remove mature and immature T  and B  cells, or reconstitution  with 
lpr/lpr fetal liver cells devoid of T  cells, failed to prevent the wasting syndrome 
or subsequent death of +/+  recipients. 
Runt  disease was also observed in  the  following combinations:  (a) +/+  mice 
reconstituted  with lpr/lpr  splenocytes from  1-mo-old donors injected intraperi- 
toneally at birth (<24 h  old) with 5  X  107  +/+  splenocytes to render the donor 
"tolerant" to antigens expressed on +/+  cells; (b) +/+  recipients thymectomized 
at  birth  and  lethally  irradiated  at  1  mo  of age,  before  transplantation  with 
lpr/lpr splenocytes or BM cells.  This group's death rate and wasting syndrome 
were  considerably  retarded  compared  to  nonthymectomized  recipients  (50% 
mortality rate at 7.2 mo posttransfer compared to 2-3 mo posttransfer, respec- 
tively);  (c)  +/+  recipients  of splenocytes  or  BM  cells  from  1-mo-old  lpr/lpr 
donors  thymectomized at  birth  and  transplanted  with  +/+  thymuses;  and  (d) 
+/+  recipients  thymectomized  and  transplanted  with  lpr/lpr  thymuses,  then 
lethally irradiated at 2  mo of age and injected with lpr/lpr spleen or BM cells. 
Mechanisms of the Wasting Syndrome.  Although the wasting syndrome of +/+ 
mice receiving lpr/lpr cells resembled subacute GVHD, the causes and means of THEOFILOPOULOS  ET  AL. 
TABLE  IV 
Primary and Secondary CML Responses Between MRL lpr/lpr and 
MRL 4-/+ Cells 
Stimula-  Specific lysis* 
Effector  tot/Target*  PrimaryJ  Secondaryl 
% 
+/+  lpr/lpr  8.2 _+ 2.1  14.7 "4- 2.6 
C3H/St  -2.6 ±  1.7  82.3 _-4-  9.9 
BALB/c  76.8 +  5.3  ND  1 
lpr/lpr  +/+  4.6 4- 1.0  17.8 _  0.4 
C3H/St  -8.5 ±  3.0  74.0 +  14.3 
BALB/c  87.9 +  5.5  ND 
lpr/lpr  C3H/St  1.7 +  0.8  60.5 _+ 6.4 
+/+  1.2 ±  0.3  65.6 +  9.5 
BALB/c  73.8 +  7.1  ND 
lpr/lpr  BALB/c  79.8 +- 4.8  ND 
+/+  78.1  -+ 11.1  ND 
C3H/St  85.0 -+ 7.9  ND 
Results of five experiments with spleen cells from 1-mo-old mice. 
* Stimulator splenocytes were irradiated with 3,000  rad. Target spleno- 
cytes were prepared by preincubation for 5 d with Con A. 
* Specific lysis  was  determined  by  the formula:  (experimental  -  back- 
ground) x  100](100  -  background).  Background lysis was determined 
as the 51Cr release from target cells added  to autologous effector and 
autologous stimulator cells. 
0 Effector cells were obtained from unimmunized mice. 
! Effector cells were obtained 5 d after in vivo immunization with irradi- 
ated stimulator target splenocytes. 
1 ND, not done. 
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TABLE  V 
Frequency of Hemopoietic Precursors in MRL lpr/lpr and 
MRL 4-/+ Mice 
Bone marrow source*  Recipient*  CFU0 
lpr/lpr  lpr/Ipr  15.44 -  3.3 
+/+  +/+  11.5 -+ 3.08 
lpr/lpr  +/+  17.1  --- 2.85 
+/+  lpr]lpr  11.11 +  2.36 
*  105 BM cells in 0.5 ml i.v. 
* Recipients were given 1,200 rad irradiation. 
Counted  11  d  after  transfer.  Donors  and  recipients  were  1-mo-old 
females, six mice per group. 
induction  could  not  be  defined  with  classical  histocompatibility  studies.  There- 
fore, additional  possibilities were examined,  including:  (a) potential  activation of 
a  latent  virus by  irradiation;  (b)  generation  of cytotoxic or  suppressor  cells, and 
(c) BM resistance phenomena  attributed  to radioresistant  natural  killer (NK)-like 
cells of the host (19). 
To  examine  the  first  possibility,  100  #1  of  serum,  or  a  mixture  of  spleen, 10 
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FIGURE 4.  Effects of splenocytes from MRL lpr/lpr ~  MRL +/+ mice with runt disease on 
the proliferative response of T  and B cells from unmanipulated MRL lpr/lpr and MRL +/+ 
mice. Splenocytes from unmanipulated MRL +/+, unmanipulated MRL lpr/lpr or MRL +/+ 
recipients of MRL lpr/lpr  spleen cells with runt disease (R) were cultured either alone (2 × 
10  5 cells in 0.2 ml), or in combination (10  n cells from each group) in the presence of Con A (4 
ttg/ml) or LPS (2.5/tg/ml); 3 d later, [~H]thymidine incorporation was measured. 
thymus, and  liver cells (1.2  ×  108 cells irradiated  at 3,000 rad) from  2-mo-old 
+/+ mice suffering from wasting syndrome were injected intraperitoneally  into 
newborn  +/+  mice.  Additionally,  1-mo-old +/+  mice were lethally  irradiated 
and reconstituted with +/+ BM cells (2 X  10 7) to which an equal number of cells 
(irradiated to 3,000 rad) from wasting +/+ mice had been added before transfer. 
Neither group developed clinical or histologic evidence of wasting, even at 5 mo 
posttransfer. 
To  examine  the  possible  generation  of cytotoxic  or  suppressor  cells,  two 
experiments  were performed:  First,  spleen  cells from  mice  with  GVHD were 
tested for direct cytotoxicity on recipient and donor target cells in a  4-h  52Cr- 
release assay.  However, at effector/target cell ratios of 100:1,  50:1,  and  25:1, 
spleen cells from mice with GVHD were not cytotoxic to either type of target 
cells (data  not shown).  Second,  we examined  the  ability of cells from  wasting 
mice to inhibit mitogenic responses of T  and B cells from unmanipulated  2-mo- 
old lpr/lpr  and  +/+  mice (Fig.  4).  Cells from  unmanipulated  2-mo-old lpr/lpr 
mice had lower Con A  responses than  those from unmanipulated  +/+ mice, as 
previously  reported  (23),  but  they  showed  no  significant  differences  in  LPS 
responsiveness. Cells from wasting +/+ mice had minimal Con A responses, but 
normal  LPS responses.  Mixing lpr/lpr with  +/+  cells derived from unmanipu- 
lated mice had no effect on Con A  or LPS responsiveness in either population, 
since the mixed response was equivalent to the expected sum of the responses 
by each  cell population.  In  contrast,  mixing  cells from unmanipulated  +/+  or 
lpr/lpr mice with cells from wasting +/+ mice considerably reduced Con A, but 
not LPS responsiveness in both cell populations. 
With  regard  to  BM  resistance  phenomena,  since  NK  cell  activity  matures THEOFILOPOULOS  ET  AL.  11 
ontogenically only after the third to fourth week of life (19),  we reconstituted 
1-2 wk, rather than  1-mo-old, +/+ mice with lpr/lpr BM cells, and found that 
wasting still developed. 
Cell  Transfers  Between  C57-1pr/lpr  and  C57BL/6  Mice.  The  lpr  gene  has 
recently been transferred into C57BL/6  and the C3H/HeJ  mice (10,  11).  To 
determine whether the lpr gene-related wasting syndrome was unique to MRL 
mice  or  was  more  general,  we  performed  reciprocal  BM  transfers  between 
C57BL/6 lpr/lpr and C57BL/6 mice. Like MRL mice, C57BL/6 mice given C57 
lpr/lpr BM cells developed GVHD and wasting within 3-5 mo, whereas in the 
converse situation (C57BL/6 --~ C57 lpr/lpr) no runt disease developed within 5 
mo. 
Discussion 
Establishing the means by which systemic autoimmune diseases develop led us 
to  transplant  hemopoietic cells reciprocally between  two  murine lines  (MRL 
lpr/lpr  and  MRL  +/+)  with  small  differences in  their  genomes  (<1%),  but 
significant phenotypic differences in  the degree of lymphoid hyperplasia and 
pace  of  SLE-like  syndrome  they  develop.  The  present  data  show  that  (a) 
hemopoietic cells of such mice effectively induce the respective disease pheno- 
types in  lethally irradiated  syngeneic recipients;  (b)  cells  of MRL  +/+  mice 
maturing in an  MRL lpr/lpr  environment essentially retain the donor disease 
phenotype, i.e., they induce lupus relatively late in life and without lymphade- 
nopathy, but (c) MRI. lpr/lpr cells provoke an unexpected phenomenon when 
transplanted  into  irradiated  MRL  +/+  recipients;  they induce  not  the  early 
severe lupus and lymphadenopathy of the donor, but a severe wasting syndrome 
resembling subacute GVHD, as classically defined by Rappaport et al. (24). 
The pace at  which disease develops in  irradiated  MRL  lpr/lpr  mice trans- 
planted with MRL lpr/lpr spleen or BM cells is the same regardless of whether 
the transferred cells originate from prediseased or diseased donors. Moreover, 
fetal liver cells induce the typical disease (data not shown). These findings suggest 
that the active ceil being transferred is the stem cell, and that the age-dependent 
development of autoimmunity and lymphadenopathy does not result from an 
accumulation of defects at the stem cell level, i.e., stem cells from MRL lpr/lpr 
mice of any age are at the same stage of abnormality. Prolonged survival and 
absence of lymphoid hyperplasia in MRL lpr/lpr recipients of MRL +/+ hemo- 
poietic cells indicate the irrelevance of the Ipr/lpr nonlymphoid environment in 
this  disease.  In  our  previous  thymic transplants  between these two  lines,  the 
thymic genotype was of no consequence to the pace and characteristics of the 
disease (13), despite the need of a thymus for expression of the lpr/lpr phenotype 
(13, 25). Experiments with other types of lupus mice (NZB, BXSB) also showed 
that  the  origin  of  the  transplanted  cells  and  not  the  irradiated  recipients' 
environment is the determining factor in disease development. Thus, in recip- 
rocal spleen and BM cell transfers between the early-life disease-developing male 
and  the  late-life disease-developing female BXSB  mice, the timing of disease 
onset is dependent on the sex of the donor and not of the recipient (7). Similarly, 
NZB hemopoietic cells transferred into H-2-compatible irradiated normal mice 
cause autoimmune disease, whereas normal cells transferred into irradiated NZB 12  Ipr  GENE  1N  TRANSPLANTATION 
mice do not (1-3). 
The unexpected finding in the present study was the development of a severe 
wasting syndrome in MRL +/+ recipients of MRL lpr/lpr cells. Such mice failed 
to develop lymphoid hyperplasia and autoantibodies, as the origin of the donor 
cells would have dictated.  Of course, the wasting syndrome may well preclude 
the  development  of the  other  characteristics.  On  the  basis  of their  breeding 
history,  MRL lpr/lpr and  MRL +/+  mice are  considered congenic except for 
the lpr locus (5).  Therefore,  this  locus, or an extremely closely-linked genetic 
element(s), could be implicated  in  the observed phenomenon.  A  similar  unidi- 
rectional wasting syndrome followed cell transfers between C57BL/6 lpr/lpr and 
C57BL/6 +/+ mice, reinforcing this gene's potential participation. 
The lpr gene might promote the appearance ofa GVHD-like disease in at least 
two ways. First,  the Ipr locus may directly control a  cell surface antigen.  If so, 
the lpr mutation could result in either a new or defective product or, more likely 
in light of the unidirectional nature of the GVHD, inability to express a product 
on  the  cell  surface.  Second,  the  lpr  locus  might  be  a  regulatory  gene  that 
influences one or more other regulatory or structural genes, thereby interfering 
with, blocking, or altering the expression of their products. As a result, the MRL 
+/+ cells that do express this putative antigen(s) are recognized as foreign, and 
stimulate a  graft-vs.-host reaction.  The  fact that  MRL +/+  mice could not be 
rescued  from  the  wasting  syndrome  by  the  simultaneous  administration  of 
lpr/lpr and +/+ cells would also tend to support this notion. 
Genetic linkage of lpr has not yet been established, despite the fact that ~47% 
of the autosomal genome has been tested, and 27 linkage markers, including H- 
2, on various chromosomes have been analyzed (5).  Nevertheless, interdepend- 
ence or interaction  between the !pr gene and  the  H-2 complex was suggested 
when Cronin et al. (26) found that certain monocytic-like cell lines derived from 
MRL lpr/lpr lymph nodes expressed low amounts of I-A  k, I-E  k (the MRL lpr/lpr 
mouse has been typed as H-2  k) and inappropriately high amounts of H-2K  d, H- 
2D  a, I-A  d and LE  d. The authors concluded that a minute subset of monocytes in 
MRL lpr/lpr mice expressed inappropriate H-2d-I-A  d antigens, perhaps derived 
from  the  LG/J  (H-2  d)  ancestor,  which  contributes  75%  of the  MRL lpr/lpr 
genome. Additionally, an increased frequency of Iak-positive peritoneal macro- 
phages appeared at 3 mo of age; at or around the onset of lymphoproliferation 
in  MRL lpr/lpr  mice (27-29).  Such increases have not been observed in  MRL 
+/+ mice, nor in other lpr homozygous lines (C3H lpr/lpr, C57BL/6 lpr/lpr) of 
mice (28, 29). The relevance of these observations to the GVHD-Iike phenome- 
non is difficult to evaluate at present. 
Attempts to identify lpr/lpr-associated lymphocyte surface antigens to account 
for the  GVHD have  met with little success. Thus,  compared to the  +/+  cells, 
MRL lpr/lpr lymphocytes possess a  lower electronegative charge (30), a  higher 
number of potassium channels (31), alterations  of terminal  carbohydrate struc- 
ture of glycolipids and  glycoproteins (32), and lower (Con A) or higher (Helix 
pomatia)  number  of receptor  sites  for  certain  lectins  (30).  Furthermore,  the 
proliferating T  cells of lpr/lpr mice express inappropriate alloantigens associated 
with pre-B/B cells (33-35). However, attempts to produce antibodies specific for 
the proliferating  T  cells were unsuccessful (A.  N. Theofiiopoulos, unpublished 
observations). The unidirectional  nature of the wasting syndrome suggests that THEOFILOPOULOS  ET  AL.  13 
the lpr gene does not encode a unique product on the lymphocyte surface, but 
rather deletes or alters a normal product (5). 
Whatever modifications are introduced by the lpr gene on lymphocyte surfaces, 
compatibility testing does not reveal them, i.e., lpr/lpr ceils do not evoke in the 
presence of +/+ cells significant primary or secondary MLR or CML reactions, 
nor a  positive Simonsen splenomegaly assay. Clearly, minor histocompatibility 
differences cause minimal splenomegaly unless the donors are presensitized (36). 
Similarly, cytotoxic reactions to minor histocompatibility antigens are very weak 
except in  secondary responses  (37),  but  even secondary responses were weak 
between MRL lpr/lpr  and  MRL  +/+  cells.  At any rate,  loci outside the H-2 
complex have been cited in other examples of runt disease after cell transfers 
between certain combinations of mice (20, 21, 38). 
GVHD observed after BM transplants between major or minor histocompati- 
bility antigen-mismatched individuals possibly reflects alloaggression mediated 
not by stem cells or their progeny, but  by mature T  cells contaminating the 
spleen (30- 35 % T  cells) or BM (2-7 % T  cells) inocula (20, 21). The basis of this 
view is the observation that GVHD does not develop if such inocula have been 
treated with anti-Thy-1 (22), anti-Thy-1 plus C (20,  21), or certain lectins that 
remove T  cells (12). GVHD also does not appear, even across major histocom- 
patibility  complex  barriers,  if  fetal  liver  cells  devoid  of T  cells  have  been 
transferred (39,  40).  In these instances, the T  cell precursors maturing in the 
irradiated hosts' thymic environment are presumably tolerized. However, in the 
case of the MRL lpr/lpr ~  MRL +/+  transfers, none of these manipulations 
affected the associated GVHD, for unknown reasons. This runt syndrome may 
not have been mediated by T  cells, considering that thymectomy of the MRL 
+/+ recipients, although delaying, was not preventative. Alternatively, T  cells 
of the  MRL  lpr/lpr  donor  maturing  in  the  MRL  +/+  environment may be 
refractory to  tolerance induction,  as  described in  other systems (41,  42).  Of 
particular interest, education of the MRL lpr/lpr cells in an MRL +/+ thymic 
environment before transfer to the MRL +/+  recipients, or transfer of MRL 
lpr/lpr  cells into  MRL  +/+  mice that had been thymectomized and given an 
MRL lpr/lpr  thymus just after birth, did not prevent the GVHD.  Apparently, 
the MRL Ipr/lpr thymic genotype has no unique property that allows the MRL 
lpr/lpr  stem cells to acquire characteristics necessary for the initiation of the 
graft-vs.-host phenomenon. Furthermore, these data suggest an intrinsic defect 
in the tolerizability of lpr/lpr stem cells. 
The possibility of BM resistance (19) was also considered here. In this phenom- 
enon, grafts of hemopoietic cells fail or grow poorly in certain lethally irradiated 
allogeneic mice, including F~ hybrid recipients of parental cells (43). Cudkowitz 
(44) suggested that special recessive, tissue-specific hemopoietic histocompatibil- 
ity (Hh) genes, rather than classic histocompatibility genes, determine the fate of 
hemopoietic grafts. However, further consideration led others to conclude (45) 
that both class I and class II major histocompatibility genes, and not a special Hh 
gene, control hemopoietic resistance. The resistance is effected by an unusual 
host-vs.-graft reaction that is radioresistant, independent of the thymus, and is 
observed in F1 mice injected with parental cells; these requirements were met in 
our  MRL  lpr/lpr  ~  MRL  +/+  and  MRL  lpr/lpr  ~  (MRL  lpr/lpr  X  MRL 
+/+)Fa transfers. However, resistance to hemopoietic grafts matures only after 14  lpr  GENE  IN  TRANSPLANTATION 
the 3-4 wk of life, concomitantly with the appearance of NK cells (19, 43). Yet, 
1-2-wk-old MRL +/+ mice used as recipients of MRL lpr/lpr cells still developed 
the runt  syndrome.  Furthermore,  BM  inocula of MRL lpr/lpr  mice induced 
sufficient numbers of CFU  in  irradiated  MRL  +/+  recipients.  Both  of these 
findings indicate that the runt disease in MRL lpr/lpr ~  MRL +/+ transfers was 
not mediated by a BM resistance phenomenon. 
Because runt disease is lethal, and because donor T  cells are required for its 
induction, it has been assumed that it is caused by donor cytotoxic T  lymphocytes 
(46).  However, runt disease also seems to develop via generation of suppressor 
T  cells that inhibit physiologic cell proliferation in  lymphohemopoietic tissues 
(38, 47). Such suppression caused by graft-vs.-host reactions is nonspecific, since 
it affects not only hemopoiesis of the recipients, but also that of the donor strain 
used for induction of the reaction (47-50).  In the case of the MRL lpr/lpr and 
MRL +/+ mice, none of our assays showed significant cytotoxic T cells. However, 
cells of mice with  wasting  syndrome suppressed  Con  A-induced proliferative 
responses of MRL lpr/lpr  and MRL  +/+ splenocytes. These results,  together 
with the severe lymphopenia and anemia of the MRL +/+  recipients of MRL 
Ipr/lpr  cells, suggest that,  following the initial  repopulation,  the graft-vs.-host 
reaction instigates formation of nonspecific suppressor cells of hemopoiesis and 
lymphopoiesis. 
The studies reported here indicate that a difference between two lines of mice 
at  the lpr  locus or  closely-linked genetic elements results  in  a  unidirectional 
GVHD-like reaction and runt disease. This type of GVHD may be mediated by 
a  radiosensitive immature T  cell in  the spleen  or  BM  inocula,  since it  is  not 
abrogated by elimination of mature cells before transfer, and it can be induced 
by fetal liver cells. The model described here may be useful in further studies of 
the immunobiology of GVHD due to non-H-2 products, in understanding the 
means by which the lpr gene adversely affects lymphocyte regulation and ho- 
meostasis, and for identifying the modes of its actions. 
Summary 
Hemopoietic ceils  have been  reciprocally transferred between two  lines of 
mice (MRL lpr/lpr and MRL +/+) that are congenic, differing only at the lpr 
(lymphoproliferation) and possibly closely linked genes. The lpr strain develops 
a significantly more severe and fast-paced lupus-like syndrome than +/+ strain, 
along with a  substantially larger lymphoid mass.  The results showed that:  (a) 
hemopoietic cells of such mice were sufficient to induce the respective disease 
phenotypes in lethally irradiated syngeneic recipients; (b) cells of MRL +/+ mice 
maturing in an MRL lpr/lpr  environment essentially retained the disease-pro- 
ducing characteristics of the  donor,  i.e.,  they induced late-life lupus  without 
lymphadenopathy; but (c) MRL lpr/lpr  cells transferred into irradiated  MRL 
+/+  recipients  unexpectedly failed  to  induce  the  early-life severe lupus  and 
lymphoid hyperplasia of the donor,  instead they caused a  severe wasting syn- 
drome resembling, in many respects, graft-vs.-host disease (GVHD). This GVHD- 
like syndrome developed after transfer of MRL lpr/lpr fetal liver, bone marrow, 
or spleen cells, and was not abrogated by elimination of T  cells from the inocula. 
Thymectomy of the  MRL  +/+  recipients retarded,  but did  not prevent,  the THEOFILOPOULOS ET  AL.  15 
wasting disease.  The  unidirectional  nature  of this disease suggests  that  the lpr 
mutation  conferred  either  a  structural  or  regulatory  defect  that  interferred, 
blocked, or altered the expression or structure of certain lymphocyte antigen(s). 
As a  result, the MRL +/+  cells that did express this antigen(s) were recognized 
as  foreign,  and  stimulated  a  graft-vs.-host reaction.  These findings  may allow 
definition of a  new kind of rejection phenomenon caused by non-H-2 products, 
and may extend our understanding of the means by which the lpr gene adversely 
affects lymphocyte regulation and homeostasis. 
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